tiprankstipranks
Trending News
More News >
Grifols SA (GRFS)
:GRFS

Grifols SA (GRFS) Price & Analysis

Compare
470 Followers

GRFS Stock Chart & Stats

$8.78
-$0.21(-2.68%)
At close: 4:00 PM EST
$8.78
-$0.21(-2.68%)

Grifols SA News

GRFS FAQ

What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $6.19 and its highest was $11.14 in the past 12 months.
    What is Grifols SA’s market cap?
    Grifols SA’s market cap is $7.59B.
      When is Grifols SA’s upcoming earnings report date?
      Grifols SA’s upcoming earnings report date is Feb 26, 2026 which is in 75 days.
        How were Grifols SA’s earnings last quarter?
        Grifols SA released its earnings results on Nov 04, 2025. The company reported $0.218 earnings per share for the quarter, missing the consensus estimate of $0.242 by -$0.024.
          Is Grifols SA overvalued?
          According to Wall Street analysts Grifols SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Grifols SA pay dividends?
            Grifols SA pays a Annually dividend of $0.142 which represents an annual dividend yield of 1.55%. See more information on Grifols SA dividends here
              What is Grifols SA’s EPS estimate?
              Grifols SA’s EPS estimate is 0.29.
                How many shares outstanding does Grifols SA have?
                Grifols SA has 261,425,100 shares outstanding.
                  What happened to Grifols SA’s price movement after its last earnings report?
                  Grifols SA reported an EPS of $0.218 in its last earnings report, missing expectations of $0.242. Following the earnings report the stock price went down -2.227%.
                    Which hedge fund is a major shareholder of Grifols SA?
                    Currently, no hedge funds are holding shares in GRFS

                    Company Description

                    Grifols SA

                    Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in the production of plasma-derived therapies and biopharmaceuticals. The company operates primarily in the biotechnology sector, focusing on the development, manufacturing, and marketing of innovative products for the treatment of various medical conditions, including hemophilia, immunodeficiencies, and neurological disorders. Grifols' core products include immunoglobulins, albumin, and clotting factor concentrates, which are derived from human plasma and used in critical care settings and for patients with chronic diseases.

                    Grifols SA (GRFS) Earnings & Revenues

                    GRFS Company Deck

                    GRFS Earnings Call

                    Q3 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The earnings call highlights Grifols' robust financial performance, with significant revenue growth, improved adjusted EBITDA, and strengthened free cash flow. The company has made progress in deleveraging and gaining market share, particularly in the immunoglobulins franchise. However, challenges such as pricing pressures in China and exchange rate headwinds persist, along with a delay in regulatory approval for fibrinogen in the U.S. Despite these challenges, the overall sentiment leans towards positive, given the strong financial and operational metrics.View all GRFS earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Amgen
                    Bristol-Myers Squibb
                    Gilead Sciences
                    GlaxoSmithKline
                    Sanofi

                    Ownership Overview

                    8.50%14.10%76.46%
                    Insiders
                    14.10% Other Institutional Investors
                    76.46% Public Companies and
                    Individual Investors
                    Popular Stocks